A Systems Biological Approach Coupling Reward Gene Polymorphisms and aNutraceutical (KB220Z) Pro-Dopamine Regulator (PDR) as Putative“Standard of Care” to Treat Reward Deficiency Syndrome (RDS): EmergingEvidence - Based Scientific Induction of “Dopamine Homeostasis”
暂无分享,去创建一个
K. Blum | P. Thanos | R. Badgaiyan | D. Baron | D. Bagchi | B. Downs | R. Brewer | A. Bowirrat
[1] Thomas J. H. Chen,et al. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. , 1996, Pharmacogenetics.
[2] K. Blum,et al. The effects of residential dual diagnosis treatment on alcohol abuse , 2017, Journal of systems and integrative neuroscience.
[3] K. Blum,et al. Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence , 2013, Journal of addiction research & therapy.
[4] K. Blum,et al. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. , 2018, Frontiers in bioscience.
[5] K. Blum,et al. Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. , 2016 .
[6] D. Comings,et al. Reward deficiency syndrome: genetic aspects of behavioral disorders. , 2000, Progress in brain research.
[7] K. Blum,et al. Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS) , 2014, Molecular Neurobiology.
[8] Blum Kenneth,et al. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated) , 2018, CPQ neurology and psychology.
[9] K. Blum,et al. Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. , 2011, Journal of genetic syndromes & gene therapy.
[10] Margaret A. Madigan,et al. Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). , 2017, Global journal of addiction & rehabilitation medicine.
[11] K. Blum,et al. The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery , 2015, Journal of reward deficiency syndrome.
[12] K. Blum,et al. Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause. , 2017, Frontiers in bioscience.
[13] Margaret A. Madigan,et al. Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2 Agonist Therapy: Part 2 , 2010, Postgraduate medicine.
[14] K. Blum,et al. Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic. , 2018, SEJ surgery and pain.
[15] K. Blum,et al. Dopamine Genetics and Function in Food and Substance Abuse. , 2013, Journal of genetic syndromes & gene therapy.
[16] K. Blum,et al. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. , 2012, Journal of genetic syndromes & gene therapy.
[17] N. Volkow,et al. Pain and suicidality: Insights from reward and addiction neuroscience , 2013, Progress in Neurobiology.
[18] K. Blum,et al. Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake , 2016, Clinical medical reviews and case reports.
[19] Nick C Fox,et al. Analysis of shared heritability in common disorders of the brain , 2018, Science.
[20] K. Blum,et al. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS) , 2020, Journal of the Neurological Sciences.
[21] K. Blum,et al. Sex, Drugs, and Rock ‘N’ Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms , 2012, Journal of psychoactive drugs.
[22] Febo,et al. Coupling Neurogenetics ( GARS TM ) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome ( RDS ) : Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms Journal of Reward Deficiency Syndrome , 2016 .
[23] K. Blum,et al. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD) , 2019, Journal of systems and integrative neuroscience.
[24] K. Blum,et al. The benefits of genetic addiction risk score (GARS™) and pro-dopamine regulation in combating suicide in the American Indian population. , 2018, Journal of systems and integrative neuroscience.
[25] K. Blum,et al. Pharmacotherapies for Overeating and Obesity. , 2013, Journal of genetic syndromes & gene therapy.
[26] Kenneth Blum,et al. Dopamine and glucose, obesity, and reward deficiency syndrome , 2014, Front. Psychol..
[27] K. Blum,et al. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms , 2015, Journal of reward deficiency syndrome.
[28] K. Blum,et al. Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis , 2018, The Journal of the American Osteopathic Association.
[29] Thomas J. H. Chen,et al. Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. , 2018, Frontiers in bioscience.
[30] Margaret A. Madigan,et al. KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit? , 2016, Journal of reward deficiency syndrome and addiction science.
[31] K. Blum,et al. Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization , 2019, Molecular Neurobiology.
[32] Thomas J. H. Chen,et al. Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report. , 2012, Food & function.
[33] K. Blum,et al. Allelic association of human dopamine D2 receptor gene in alcoholism. , 1990, JAMA.
[34] William B. Downs,et al. Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study , 2012, Journal of psychoactive drugs.
[35] Thomas J. H. Chen,et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary , 2008, Theoretical Biology and Medical Modelling.
[36] K. Blum,et al. Putative Dopamine Agonist (KB220Z) Attenuates Lucid Nightmares in PTSD Patients: Role of Enhanced Brain Reward Functional Connectivity and Homeostasis Redeeming Joy , 2015, Journal of behavioral addictions.
[37] William B. Downs,et al. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. , 2019, Current pharmaceutical biotechnology.
[38] K. Blum,et al. Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission , 2017, Journal of systems and integrative neuroscience.
[39] Thomas J. H. Chen,et al. LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome , 2008, Advances in therapy.
[40] K. Blum,et al. Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats , 2020, Behavioural Brain Research.
[41] K. Blum,et al. Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)? , 2018, Journal of systems and integrative neuroscience.
[42] K. Blum,et al. Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies , 2018, Journal of systems and integrative neuroscience.
[43] Thomas J. H. Chen,et al. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. , 1995, Pharmacogenetics.
[44] William B. Downs,et al. Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. , 2013, Journal of addiction research & therapy.
[45] K. Blum,et al. Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term , 2016, Journal of reward deficiency syndrome and addiction science.
[46] K. Blum,et al. Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors , 2018, Front. Psychiatry.
[47] K. Blum,et al. “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic , 2017, Journal of systems and integrative neuroscience.
[48] K. Blum,et al. Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD , 2018, Journal of behavioral addictions.
[49] K. Blum,et al. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS) , 2017, Substance use & misuse.
[50] K. Blum,et al. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction , 2015, Journal of reward deficiency syndrome.
[51] Brijesh Singh Yadav,et al. Recent Advances in the System Biology-based Target Identification and Drug Discovery. , 2018, Current topics in medicinal chemistry.
[52] K. Blum,et al. Addiction Treatment in America: After Money or Aftercare? , 2015, Journal of reward deficiency syndrome.
[53] K. Blum,et al. Death by Opioids: Are there non-addictive scientific solutions? , 2019, Journal of systems and integrative neuroscience.
[54] K. Blum,et al. Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs) , 2019, Journal of systems and integrative neuroscience.
[55] M. El-Haram,et al. A critical review of reductionist approaches for assessing the progress towards sustainability , 2008 .
[56] Thomas J. H. Chen,et al. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? , 2009, Medical hypotheses.
[57] K. Blum,et al. Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. , 2018, EC psychology and psychiatry.
[58] C. A. Gordon,et al. Reward deficiency syndrome in obesity: A preliminary cross-sectional trial with a genotrim variant , 2006, Advances in therapy.
[59] T. Ideker,et al. A decade of systems biology. , 2010, Annual review of cell and developmental biology.
[60] K. Blum,et al. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. , 2020, Current psychopharmacology.
[61] A. Kaye,et al. The Opioid Crisis: a Comprehensive Overview , 2018, Current Pain and Headache Reports.
[62] K. Blum,et al. “Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America , 2016, Journal of systems and integrative neuroscience.
[63] K. Blum,et al. Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns , 2014, Journal of addiction research & therapy.
[64] K. Blum,et al. The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD). , 2018, International journal of genomics and data mining.
[65] K. Blum,et al. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. , 1988, Alcohol.
[66] K. Blum,et al. THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. , 2016, Precision medicine.
[67] K. Blum,et al. Substance use disorder a bio-directional subset of reward deficiency syndrome. , 2017, Frontiers in bioscience.
[68] K. Blum,et al. Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. , 2016, Open journal of clinical & medical case reports.
[69] K. Blum,et al. GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA. , 2017, Precision medicine.
[70] K. Blum,et al. Acute Intravenous Synaptamine Complex Variant KB220™ “Normalizes” Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports , 2010, Postgraduate medicine.
[71] Louise Kaplan. Medication-assisted treatment for opioid use disorder. , 2018, The Nurse practitioner.
[72] K. Blum,et al. Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone? , 2017, Journal of systems and integrative neuroscience.
[73] K. Blum,et al. Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. , 2018, Current trends in medical diagnostic methods.
[74] K. Blum,et al. Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS) , 2017, Journal of reward deficiency syndrome and addiction science.
[75] K. Blum,et al. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. , 2018, Biomedical journal of scientific & technical research.
[76] Reductionist thinking and animal models in neuropsychiatric research , 2019, Behavioral and Brain Sciences.